Downgrading of a G3 Neuroendocrine Tumor to a G2 Tumor: Can First-Line Cytotoxic Chemotherapy Change the Tumor Biology?

The antiproliferative treatment options for neuroendocrine tumors (NET)/neuroendocrine carcinomas of the gastrointestinal tract critically depend on the proliferation rate, evaluated by immunohistochemical staining for Ki-67. According to their grading, tumors are treated with somatostatin analogs,...

Descripción completa

Detalles Bibliográficos
Autores principales: Blesl, Andreas, Krones, Elisabeth, Pollheimer, Marion J., Haybaeck, Johannes, Wiesspeiner, Ulrike, Lipp, Rainer W., Kump, Patrizia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5803685/
https://www.ncbi.nlm.nih.gov/pubmed/29430237
http://dx.doi.org/10.1159/000484473
_version_ 1783298695316373504
author Blesl, Andreas
Krones, Elisabeth
Pollheimer, Marion J.
Haybaeck, Johannes
Wiesspeiner, Ulrike
Lipp, Rainer W.
Kump, Patrizia
author_facet Blesl, Andreas
Krones, Elisabeth
Pollheimer, Marion J.
Haybaeck, Johannes
Wiesspeiner, Ulrike
Lipp, Rainer W.
Kump, Patrizia
author_sort Blesl, Andreas
collection PubMed
description The antiproliferative treatment options for neuroendocrine tumors (NET)/neuroendocrine carcinomas of the gastrointestinal tract critically depend on the proliferation rate, evaluated by immunohistochemical staining for Ki-67. According to their grading, tumors are treated with somatostatin analogs, mTOR inhibitors, or cytotoxic substances. This case illustrates downgrading of a primarily highly proliferative NET achieved by a variation of cytotoxic chemotherapy regimens, followed by a combination therapy using everolimus together with lanreotide. The latter medication might lead to a good clinical response as far as tumor growth is concerned.
format Online
Article
Text
id pubmed-5803685
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-58036852018-02-09 Downgrading of a G3 Neuroendocrine Tumor to a G2 Tumor: Can First-Line Cytotoxic Chemotherapy Change the Tumor Biology? Blesl, Andreas Krones, Elisabeth Pollheimer, Marion J. Haybaeck, Johannes Wiesspeiner, Ulrike Lipp, Rainer W. Kump, Patrizia Case Rep Oncol Case Report The antiproliferative treatment options for neuroendocrine tumors (NET)/neuroendocrine carcinomas of the gastrointestinal tract critically depend on the proliferation rate, evaluated by immunohistochemical staining for Ki-67. According to their grading, tumors are treated with somatostatin analogs, mTOR inhibitors, or cytotoxic substances. This case illustrates downgrading of a primarily highly proliferative NET achieved by a variation of cytotoxic chemotherapy regimens, followed by a combination therapy using everolimus together with lanreotide. The latter medication might lead to a good clinical response as far as tumor growth is concerned. S. Karger AG 2017-12-20 /pmc/articles/PMC5803685/ /pubmed/29430237 http://dx.doi.org/10.1159/000484473 Text en Copyright © 2017 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc/4.0/ This article is licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.
spellingShingle Case Report
Blesl, Andreas
Krones, Elisabeth
Pollheimer, Marion J.
Haybaeck, Johannes
Wiesspeiner, Ulrike
Lipp, Rainer W.
Kump, Patrizia
Downgrading of a G3 Neuroendocrine Tumor to a G2 Tumor: Can First-Line Cytotoxic Chemotherapy Change the Tumor Biology?
title Downgrading of a G3 Neuroendocrine Tumor to a G2 Tumor: Can First-Line Cytotoxic Chemotherapy Change the Tumor Biology?
title_full Downgrading of a G3 Neuroendocrine Tumor to a G2 Tumor: Can First-Line Cytotoxic Chemotherapy Change the Tumor Biology?
title_fullStr Downgrading of a G3 Neuroendocrine Tumor to a G2 Tumor: Can First-Line Cytotoxic Chemotherapy Change the Tumor Biology?
title_full_unstemmed Downgrading of a G3 Neuroendocrine Tumor to a G2 Tumor: Can First-Line Cytotoxic Chemotherapy Change the Tumor Biology?
title_short Downgrading of a G3 Neuroendocrine Tumor to a G2 Tumor: Can First-Line Cytotoxic Chemotherapy Change the Tumor Biology?
title_sort downgrading of a g3 neuroendocrine tumor to a g2 tumor: can first-line cytotoxic chemotherapy change the tumor biology?
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5803685/
https://www.ncbi.nlm.nih.gov/pubmed/29430237
http://dx.doi.org/10.1159/000484473
work_keys_str_mv AT bleslandreas downgradingofag3neuroendocrinetumortoag2tumorcanfirstlinecytotoxicchemotherapychangethetumorbiology
AT kroneselisabeth downgradingofag3neuroendocrinetumortoag2tumorcanfirstlinecytotoxicchemotherapychangethetumorbiology
AT pollheimermarionj downgradingofag3neuroendocrinetumortoag2tumorcanfirstlinecytotoxicchemotherapychangethetumorbiology
AT haybaeckjohannes downgradingofag3neuroendocrinetumortoag2tumorcanfirstlinecytotoxicchemotherapychangethetumorbiology
AT wiesspeinerulrike downgradingofag3neuroendocrinetumortoag2tumorcanfirstlinecytotoxicchemotherapychangethetumorbiology
AT lipprainerw downgradingofag3neuroendocrinetumortoag2tumorcanfirstlinecytotoxicchemotherapychangethetumorbiology
AT kumppatrizia downgradingofag3neuroendocrinetumortoag2tumorcanfirstlinecytotoxicchemotherapychangethetumorbiology

Ejemplares similares